The core therapeutic application of Зверобой is the supportive management of mood and nervous system function, a use that is generally recognized within phytotherapeutic contexts. Clinical research has examined its relevance for the management of mild or moderate depression. This domain is a key area where the extract is commonly applied for symptomatic support.

Зверобой is commonly used across conditions characterized by periods of heightened symptoms, including low mood, restlessness, irritability, and chronic fatigue. It is also considered relevant for easing episodic manifestations such as mood swings associated with Premenstrual Syndrome (PMS), menopause, and Seasonal Affective Disorder (SAD). It is often used when supportive symptom management is appropriate, as it contributes to easing the overall symptom load.

“It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.”

Quick Fact: Nervous Tension Symptoms

Regulatory References

1. St. John's Wort: Usefulness and Safety overview

Official Eligibility Profile for Зверобой (St. John's Wort)

The official regulatory documentation for Hypericum perforatum (St. John's Wort) defines eligibility based on drug interactions, life stage, and age.

Classification	Population or Condition
Contraindicated	Patients with known hypersensitivity to the active substance.
Contraindicated	Patients taking a range of medicines with a narrow therapeutic index, including immunosuppressants (e.g., cyclosporine), oral contraceptives, anticoagulants (e.g., warfarin), HIV antivirals, and certain chemotherapy agents.
Not Recommended	Pregnancy and Lactation (due to insufficient safety data and potential risks).
Not Recommended	Children and Adolescents under 18 years of age (due to a lack of established safety and efficacy data).

Eligibility is also conditional upon environmental factors: patients must avoid intense UV exposure (such as prolonged sunbathing or tanning beds) due to the documented risk of photosensitivity. The medicine is generally permitted for use in adults who do not fall under any of the listed contraindications or restrictions.

Interactions with other medicines and products

Regulatory documents define the interaction profile of Зверобой (Hypericum perforatum) based on two primary mechanisms: pharmacokinetic induction and pharmacodynamic effects.

---

The most frequent interaction involves the induction of major drug-metabolizing enzymes, specifically CYP3A4, CYP2C9, and CYP2C19, as well as the drug transport protein P-glycoprotein (P-gp). This induction reduces the plasma concentrations and systemic exposure (AUC) of co-administered medicines, often leading to a loss of therapeutic effect.

Official Regulatory Restrictions

Category	Restriction Type	Key Examples of Interacting Substances
Contraindicated Combinations	Reduced efficacy/therapeutic failure	Immunosuppressants (e.g., Cyclosporine), HIV Antivirals (e.g., Indinavir), Warfarin, Digoxin, Irinotecan.
Pharmacodynamic Risk	Increased risk of adverse events	Other Serotonergic Agents (e.g., SSRIs, SNRIs, Triptans, Buspirone).
Efficacy Restriction	Reduced protective effect	Oral Contraceptives (risk of reduced contraceptive efficacy and breakthrough bleeding).

Co-administration with these contraindicated substances is strictly restricted in official labeling due to the potential for serious clinical outcomes, such as transplant rejection, treatment failure, or the development of Serotonin Syndrome. Discontinuation of Hypericum perforatum is generally followed by a washout period, as the enzymatic induction effects reverse gradually over approximately one week.

The pharmacodynamic activity of Зверобой (Hypericum perforatum extract), mediated primarily by its constituent hyperforin, is characterized by a non-selective reuptake inhibition of several key central nervous system (CNS) neurotransmitters. Hyperforin acts as an inhibitor, primarily targeting the synaptic reuptake mechanisms for serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the neuronal synapse.

This interaction is proposed to be non-competitive and indirect, potentially involving the modulation of the sodium (Na+) gradient across the plasma membrane, which is coupled to the transport function of these neurotransmitter carriers. By impeding the activity of these monoamine transporters, Зверобой increases the concentration of the monoamine neurotransmitters in the synaptic cleft. This elevated synaptic presence results in an intensified postsynaptic receptor stimulation.

Secondary mechanisms include weak, non-competitive inhibition of the enzymes Monoamine Oxidase A and B (MAO-A and MAO-B), which normally catalyze the oxidative deamination and degradation of monoamines. Chronic exposure also induces adaptive receptor changes, such as the downregulation of beta1-adrenoceptors and the upregulation of specific 5-HT receptors in cortical regions, leading to systemic modulation of monoaminergic signaling in the CNS.

Standard Administration Guidelines

The administration of Hypericum extract, often referred to as Зверобой (St. John's wort), follows established pharmaceutical protocols. The primary route for the concentrated preparations is oral, typically using capsules or film-coated tablets. Topical or cutaneous use of oil or liquid preparations is also documented for certain traditional applications like minor skin inflammations.

Dosage and Frequency

The standard adult daily dosage of the standardized dry extract generally ranges from 600 mg to 1800 mg. This total amount may be administered as a single daily dose or may be taken in divided doses, such as two or three times per day, depending on the unit strength of the product. The posology for older adults is typically the same as the general adult population, with no specific reduction indicated on the label. Due to insufficient data, the use of oral preparations for this indication is not recommended for children and adolescents under 18 years of age.

Course Duration and Administration

Solid dosage forms must be swallowed whole with sufficient liquid and are not intended to be crushed or chewed. The usage protocol defines a time frame for evaluation: the expected onset of effect is approximately four weeks. If a condition persists or worsens after a maximum of four to six weeks of use, the protocol suggests consulting a qualified healthcare practitioner.

Зверобой: Recent Clinical Evidence

Evidence for Use in Mild to Moderate Low Mood

Clinical research on Зверобой (St. John's wort) primarily consists of multiple short-term Randomized Controlled Trials (RCTs) and Meta-analyses evaluating its effect on symptoms of depression classified as mild or moderate. Studies explored how symptoms evolved over typical intervention periods (4 to 12 weeks), often comparing the extract to placebo and other pharmacological treatments. Findings indicate patterns of symptom change were measured in the observed populations; however, the certainty is reduced because results have been mixed and inconsistent across large analyses.

---

Research on Major Depression and Nervous Restlessness

Research examining the extract for Major Depression (Moderate to Severe) reports patterns of inconsistent results, with some large studies showing minimal differences compared to placebo. Consequently, the certainty remains low for this population. For Nervous Restlessness, the evidence is primarily derived from Traditional Use Documentation relied upon by regulatory bodies, reflecting decades of application, rather than new, extensive controlled trials.

---

Limitations and Unanswered Questions

The evidence base is fundamentally short-term, with limited information for long-term outcomes or sustained effects beyond the initial 12-week study duration. Evidence is limited for specific patient groups, such as adolescents and children, as clinical research has focused predominantly on adults. The research landscape also describes statistical heterogeneity (variability) across findings, meaning that results may differ based on the specific standardized formulation of the extract used.

Key Studies & References St. John's Wort: Usefulness and Safety overview (NCCIH Health Topic)

Common questions about Зверобой (FAQ)

Q: If I miss a dose, what should I do? Should I double up?

Official patient information states that if a dose is forgotten, the next usual dose should be taken at the regular time. Official information advises against taking a double dose to compensate for a forgotten one.

---

Q: What is the recommended duration for taking St. John's Wort?

Regulatory documents indicate that the initial time frame for evaluating the product's effect is typically four to six weeks. Official labeling indicates that if the condition persists or worsens after this period, a qualified healthcare practitioner should be consulted.

---

Q: Can I crush or chew the tablets before swallowing?

Official administration guidelines state that solid dosage forms, such as tablets, must be swallowed whole with a sufficient amount of liquid. They are not intended to be crushed, broken, or chewed.

---

Q: What should I do if I accidentally take too much St. John’s Wort?

Official safety information advises that if an overdose occurs, immediate assistance should be sought. This is typically done by contacting a doctor, pharmacist, or local poison control center.

---

Q: How should I dispose of expired or unused St. John’s Wort medicine?

Expired or unused Зверобой must be disposed of properly in accordance with local regulations to ensure public safety. Regulatory guidelines prohibit flushing this medication down the toilet or pouring it into a drain.

---

Q: What are the symptoms of Serotonin Syndrome to watch out for?

Serotonin Syndrome is a potential safety risk described in regulatory warnings when this product is combined with certain other medicines. Symptoms that may be experienced include agitation, confusion, a rapid heart rate, heavy sweating, fever, and a loss of muscle coordination.

---

Q: Is it safe to drink alcohol while taking St. John’s Wort?

Regulatory safety profiles indicate that the consumption of alcohol should be avoided while using this product.

How to Store and Dispose of Зверобой (St. John's Wort) Official Regulatory Information

The storage of Зверобой is strictly governed by regulatory requirements to prevent the degradation of its sensitive phytocomplex, specifically the hypericin and hyperforin components.

Storage Requirement	Official Condition (Regulatory Basis)
Temperature / Light / Moisture	Store in a cool, dark, and dry place (e.g., below 25 C to 30 C) and away from direct heat or sunlight.
Container Integrity	The product must be kept in its original container with the cap tightly closed after each use to protect from air and light.
Child Protection	Keep out of the sight and reach of children as a mandatory requirement for all medicinal products.

Disposal must adhere to official guidelines to prevent environmental contamination and ensure public safety. Expired or unused Зверобой should be properly discarded in accordance with local laws and regulations. It is strictly prohibited to flush this medication down the toilet or pour it into a drain.